A Reliable Cold Chain is a Health Equity Issue
April 21, 2026
Why temperature-controlled logistics is a critical but overlooked foundation of equitable access to medicines
4 min read
False
Advertisement
2026
This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum
April 21, 2026
Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma
3 min read
This Week’s CGT News: New FDA Genome Editing Guidance
April 20, 2026
Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T
4 min read
The Secrets of the Gut
April 20, 2026
Going beyond the gut: why microbiome testing is the next big thing in drug development
3 min read
Trends and Challenges in Nitrosamine Testing Part Four The Regulatory Landscape
April 17, 2026
Following part two, which explored the analytical challenges involved in nitrosamine testing, our experts return to offer their top tips for building a method from scratch
2 min read
Merck Expands Protein A Capabilities with JSR Chromatography Acquisition
April 16, 2026
The company says the acquisition will strengthen downstream antibody manufacturing and help biopharma customers scale more efficiently.
Cell and Gene Roundup: CAR T Breaks New Ground
April 15, 2026
A campus-built therapy enters clinical trials as researchers refine gene editing and uncover new ways to control gene expression
5 min read
Navigating Formulation Change in the EU
April 15, 2026
How to turn regulatory complexity into strategic strength
7 min read
Jonathan Van-Tam on COVID’s Next Phase
April 14, 2026
Former UK Deputy Chief Medical Officer discusses new protein-based vaccines, declining uptake, and the ongoing risks of COVID-19
4 min read
FDA Fast-Tracks Off-the-Shelf CAR-T for Aggressive T-Cell Cancers
April 14, 2026
WashU Medicine-developed WU-CART-007 has received Breakthrough Therapy designation after early clinical results in relapsed or refractory T-cell leukemias and lymphomas.
1 min read
